This study demonstrates the potential effect of KEAP1 mutation on tumor immune milieu of LUAD subtype of NSCLC patients, highlighting the potential efficacies of the immunotherapy treatment using PD‐L1 blockers in KEAP1‐wild type LUADs. The gene discussed is KEAP1; the disease is neoplasm.